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Abstract Obesity as a pathogenic disorder is a predisposing factor for cardiovascular diseases and shows an increasing
incidence in the industrialized countries. Adipokines such as leptin, adiponectin and resistin have a great impact
on the development of atherosclerosis in obesity. Elevated levels of leptin have been found to be atherogenic
whereas decreased levels of adiponectin have been proved to be anti-atherogenic in recent studies. The exact role
of resistin in the process of atherosclerosis has so far remained uncertain and controversial. In our recent work, we
studied the alteration in human paraoxonase-1 (PON1) activity and adipokine levels; furthermore, we also aimed at
identifying the potential correlation between these parameters in this metabolic disorder. We investigated the above-
mentioned parameters both in adults and in children, with regard to the emerging role of childhood obesity and to
get a clearer view of these factors during a whole lifetime. Investigating the adult population with a broad range of
body mass index (BMI) we found significantly increased leptin and significantly decreased adiponectin and resistin
levels and PON1 activity in the obese group compared to the lean controls. Adiponectin and resistin levels showed
significantly positive correlation, while leptin and BMI showed significantly negative correlation with PON1 activity.Our
findings were similar in childhood obesity: leptin showed significantly negative correlation, while adiponectin showed
significantly positive correlation with PON1 activity. We found gender differences in the univariate correlations of
leptin and adiponectin levels with PON1 activity in the adult population. In multiple regression analysis, adiponectin
proved to be an independent factor of PON1 activity both in childhood and adult obesity, furthermore thiobarbituric
acid-reactive substances (TBARS) also proved to be an independent predictor of the enzyme in adults, reflecting
the important role of oxidative stress in obesity. Investigating PON 192 Q/R polymorphism by phenotypic distribution
(A/B isoenzyme) in obese children, we found a significant correlation of PON1 arylesterase activity with leptin and
adiponectin levels, and of body fat percentage with PON1 192 B isoenzyme.According to our studies, these metabolic
changes in obesity predispose to the early development of atherosclerosis throughout our whole lifetime. Decreased
activity of PON1 and alterations in adipokine levels in childhood obesity could contribute to an early commencement
of this process, detected only later in adulthood by increased cardiovascular morbidity and mortality. Changed levels
of leptin, adiponectin, resistin and PON1 activity at all ages, just like 192 Q/R polymorphism determined by phenotypic
distribution, may be useful markers beside the general risk factors.
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Abstract Obesity as a pathogenic disorder is a predisposing factor for cardiovas-
cular diseases and shows an increasing incidence in the industrialized countries.
Adipokines such as leptin, adiponectin and resistin have a great impact on the devel-
opment of atherosclerosis in obesity. Elevated levels of leptin have been found
to be atherogenic whereas decreased levels of adiponectin have been proved to
be anti-atherogenic in recent studies. The exact role of resistin in the process of
atherosclerosis has so far remained uncertain and controversial. In our recent work,
we studied the alteration in human paraoxonase-1 (PON1) activity and adipokine
levels; furthermore, we also aimed at identifying the potential correlation between
these parameters in this metabolic disorder. We investigated the above-mentioned
parameters both in adults and in children, with regard to the emerging role of child-
hood obesity and to get a clearer view of these factors during a whole lifetime.
Investigating the adult population with a broad range of body mass index (BMI)
we found significantly increased leptin and significantly decreased adiponectin
and resistin levels and PON1 activity in the obese group compared to the lean
controls. Adiponectin and resistin levels showed significantly positive correla-
tion, while leptin and BMI showed significantly negative correlation with PON1
activity.
Our findings were similar in childhood obesity: leptin showed significantly neg-
ative correlation, while adiponectin showed significantly positive correlation with
PON1 activity. We found gender differences in the univariate correlations of lep-
tin and adiponectin levels with PON1 activity in the adult population. In multiple
regression analysis, adiponectin proved to be an independent factor of PON1 activ-
ity both in childhood and adult obesity, furthermore thiobarbituric acid-reactive
substances (TBARS) also proved to be an independent predictor of the enzyme
in adults, reflecting the important role of oxidative stress in obesity. Investigating
PON 192 Q/R polymorphism by phenotypic distribution (A/B isoenzyme) in obese
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I. Seres et al.
children, we found a significant correlation of PON1 arylesterase activity with leptin
and adiponectin levels, and of body fat percentage with PON1 192 B isoenzyme.
According to our studies, these metabolic changes in obesity predispose to the
early development of atherosclerosis throughout our whole lifetime. Decreased
activity of PON1 and alterations in adipokine levels in childhood obesity could
contribute to an early commencement of this process, detected only later in adult-
hood by increased cardiovascular morbidity and mortality. Changed levels of leptin,
adiponectin, resistin and PON1 activity at all ages, just like 192 Q/R polymorphism
determined by phenotypic distribution, may be useful markers beside the general
risk factors.
Keywords Adipokines · Leptin · Adiponectin · Resistin · Obesity · Paraoxonase-1 ·
Childhood
1 Introduction
1.1 Obesity and Atherosclerosis: The Role of Adipokines
in Atherogenesis and Lipid Peroxidation
Obesity has been identified as a major health concern, and as its level continues
to grow steadily the condition threatens to rank among the biggest causes of pre-
mature death in both the industrialized and emerging economies. Obesity is an
important determinant of atherosclerosis, but the mechanisms behind it are only
partially understood. Intra-abdominal or visceral adiposity plays a fundamental role
in the stimulation of hyperglycemia, dyslipidemia and hypertension, collectively
termed metabolic syndrome, which is one of the most significant risk factors of
cardiovascular diseases (Ford, 2005).
Previously, a direct relation was found between general obesity and markers of
oxidative stress (Mutlu-Turkoglu et al. 2003). In humans the susceptibility of lipids
to oxidative modification is an independent risk factor of coronary heart disease
(Holvoet et al. 2001). Furthermore, it was also shown that body mass index (BMI)AQ1
is one of the strongest predictors of circulating ox-LDLconcentrations (Holvoet,AQ2
2006; Ho et al. 2002). In addition, previous studies have demonstrated significant
correlations of urinary isoprostanes and ox-LDL/LDL ratio with BMI (Sjogren et al.
2005). Collectively, these findings indicate that weight is an important determi-
nant of oxidative stress. However, the mechanisms by which obesity per se could
induce increased oxidative stress are not well defined. According to one hypothesis,
oxidative stress is induced by low-grade systemic inflammation. Other factors that
have been discussed in relation to increased oxidative stress in obesity are insulin
resistance and lipoprotein abnormalities (Weinbrenner and Schroder, 2006).
Previous studies have revealed that humoral factors secreted by adipose tissue
contribute to the metabolic syndrome and cardiovascular diseases (Bełtowski et al.
2008). Adipocytes are more than passive fuel storage sites; they release numerous
























































Alteration of PON1 Activity in Adult and Childhood Obesity
some obesity-related disorders, including cardiovascular diseases, are associated
with dysfunction of adipose tissue (Katagiri et al. 2007).
Leptin, the product of ob gene, is a 16 kDa peptide hormone produced mainly
by differentiated adipocytes, although leptin expression has been demonstrated in
other tissues such as liver, skeletal muscle and placenta. Leptin acts on the central
nervous system suppressing food intake and stimulating energy expenditure. Leptin
receptors have been found ubiquitously in the body, indicating a general role of
leptin. The concentration of leptin is directly proportional to total body fat, and thus
obese subjects have usually higher leptin concentrations than non-obese subjects.
However, not only the rare human leptin deficiency, but also resistance to the effect
of leptin, which is common in obesity, is associated with weight gain. Numerous
observations indicate a correlation between serum leptin and cardiovascular diseases
(Wannamethee et al. 2007; Patel et al. 2008).
Leptin contributes to the pathogenesis of atherosclerosis by several mechanisms
including the enhancement of oxidative stress. Leptin increases the generation
of reactive oxygen species by activating c-Jun amino-terminal kinase, AP-1 and
nuclear factor kappa B pathways (Bouloumie et al. 1999). Hyperleptinaemia pro-
motes vascular inflammation, stiffness, calcification and proliferation by increasing
oxidative stress. ROS enhances the expression of adhesion molecules, which pro-
mote the chemotaxis of monocytes in the vessel wall (Curat et al. 2004). By
increasing oxidative stress and activating protein kinase C, leptin also increases the
production of proatherogenic lipoprotein lipase (LPL) in macrophages. LPL pro-
motes the retention of lipoproteins in the subendothelial space, favors monocyte
adhesion and stimulates the transformation of macrophages into foam cells (Dubey
and Hersong, 2006). In rats, leptin administration decreased the activity of paraox-
onase, and increased plasma and urinary concentrations of isoprostanes reflecting
increased oxidative stress (Beltowski et al. 2003; Beltowski, 2006).
Adiponectin is an adipocyte-specific protein with roles in glucose and lipid home-
ostasis. A negative correlation between obesity and circulating adiponectin has
been shown, and decreased adiponectin concentrations are associated with insulin
resistance and hyperinsulinemia (Szmitko et al. 2007). Adiponectin also plays anti-
atherogenic and anti-inflammatory roles. Accordingly, adiponectin concentrations
are decreased in patients with coronary artery disease. The mechanisms underlying
the role of adiponectin in lipid peroxidation may involve the regulation of pro-
teins associated with triglyceride metabolism, including CD36, acyl CoA oxidase,
5′-AMP-activated protein kinase and peroxisome proliferator-activated receptor γ
(Meier and Gressner, 2004).
Resistin is another adipocyte-specific protein with unknown physiologic roles.
Data obtained from animal models suggest that resistin induces insulin resistance.
Human studies demonstrated conflicting results in obesity (Rabe et al. 2008). Some
of them found a positive correlation between resistin and BMI. Furthermore, resistin
may be involved in the regulation of cell proliferation and in the differentiation of
fat cells, and in chronic inflammatory reactions associated with obesity (Meier and
Gressner, 2004). The role of resistin in the development of obesity-related vascular
























































I. Seres et al.
Obesity is associated with derangements in lipid profile, called atherogenic
lipid profile, consisting of elevated ApoB and triglyceride levels and low HDL
cholesterol. HDL is able to intervene at different stages of the atherosclerotic pro-
cess (Rosenson, 2006). The antioxidant effect of HDL is mainly provided by the
human paraoxonase enzyme 1 (PON1). PON1 has been shown to protect LDL from
oxidative modification by hydrolyzing lipid hydroperoxides and cholesterol ester
hydroperoxides (esterase activity), with peroxidase activity that reducing peroxides
to their respective hydroxides and thiolactonase activity hydrolyzing homocysteine
thiolactone, thus protecting proteins from homocysteinylation (Beltowski, 2005).
Serum PON1 activity has been shown to be decreased in several diseases
with disturbed lipid metabolism that are associated with accelerated atherogenesis,
e.g., in diabetes mellitus (Mackness and Durrington, 1995), hypercholesterolemia
(Tomás et al. 2000), coronary heart disease (Mackness et al. 2004), and in
hemodialysis patients (Paragh et al. 1998), and with aging (Seres et al. 2004).
1.2 Relationship of Leptin to PON1
There are only a few studies that have examined the effects of leptin on PON1
activity and none has investigated the correlation between adiponectin, resistin and
PON1 activity.
1.2.1 Animal Studies
It was demonstrated that leptin administered for 7 days decreased plasma PON1
activity and induced oxidative stress in rats (Beltowski, 2005). In addition, leptin
reduced PON1 activity in the aorta, renal cortex and medulla but not in the heart,
lung or liver. Interestingly, leptin decreased PON1 activity only in tissues in which
it stimulated oxidative stress. These data suggest that leptin-induced decrease in
PON1 in tissues results from excessive ROS production, consistent with a well-
known inactivation of the enzyme by oxidative processes which may be involved in
atherogenesis in hyperleptinemic obese individuals.
1.2.2 Human Studies
An inverse relation of PON1 with obesity and serum leptin levels has been demon-
strated. Ferretti et al. demonstrated that the increase in oxidative stress in HDL and
LDL of obese subjects (monitored by the levels of lipid hydroperoxides in HDL and
LDL) was associated with a decrease of PON1 activity in isolated HDL (Ferretti
et al. 2005). Uzun et al have also shown an inverse correlation between serum lep-
tin levels and PON1 activity in morbid obesity after gastric banding (Uzun et al.
2004). These data suggest that hyperleptinemia could lead to reduced PON1 activ-
ity in humans. However, in our previous work we have showed that hyperleptinemia
occurring in chronic renal failure was not responsible for decreased paraoxonase
activity (Varga et al. 2006). Moreover, we found a positive correlation between
leptin and PON1 activity in hemodialysis (HD) patients. This relationship might
























































Alteration of PON1 Activity in Adult and Childhood Obesity
compared to the group with BMI < 25 kg/m2. However, the reason for enhanced
PON1 activity in the high BMI group of HD patients remains unknown.
The above-mentioned studies were performed on animal models, on isolated
HDL or in HD patients with special metabolic conditions. However, the relation of
these adipokines – leptin, adiponectin and resistin – to PON1 has not been clarified
in obesity.
The goal of our study was to examine the relationship between adipokines
and PON1 activity in obese adults and obese children (when the cardiovascular
complications are not yet manifested).
In order to magnify the impact of obesity on the investigated parameters, we
selected the adult study population with a broad range of BMI ranging from 19 to 53
with a mean of 34.2 (± 7.11) kg/m2. Patients were divided into three groups accord-
ing to BMI values, and were age- and sex-matched (Bajnok et al. 2007). Obese
(BMI = 28–39.9 kg/m2) and morbidly obese (BMI > 40 kg/m2) patients had signif-
icantly higher blood pressures and plasma glucose levels and had atherogenic lipid
profiles compared to lean subjects (BMI = 20–24.9 kg/m2).
We found a significant negative correlation between PON1 activity and BMI
(r = –0.503, p < 0.001). According to BMI categories, we found that obese and
morbidly obese patients had significantly lower PON1 activity compared to lean
subjects (Fig. 1a). Serum leptin concentration was significantly higher in both
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A B
C
Fig. 1 PON1 paraoxonase activities (a) and serum leptin concentrations (b) in the different BMI
























































I. Seres et al.
between PON1 activity and leptin levels, we found a significant negative corre-
lation between these two parameters, similar to animal studies (r = –0.38, p <
0.001, Fig 1c). The relationship between leptin and PON1 was also evaluated in
male and female subjects separately, and a stronger correlation was found among
men (r = –0.50, p <0.01) than among women (r = –0.28, p = 0.06) (Bajnok
et al. 2007).
2 Relationship of Adipokines to PON1 in Adult Obesity
2.1 Relationship of Adiponectin to PON1
It was previously demonstrated that adiponectin levels in obese patients were sig-
nificantly decreased and inversely correlated with both body weight and fat mass
(Díez and Iglesias, 2003). In confirming this well-known fact, we also demon-
strated that the obese and morbidly obese patient groups had significantly lower
adiponectin levels compared to the lean group (Fig. 2a). Our results show a neg-
ative and significant correlation between adiponectin levels and BMI (r = –0.38,
p < 0.001) (Fig. 2b). Since several in vivo and in vitro studies have reported that
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Fig. 2 Adiponectin levels in the different BMI categories (a), and correlations between

























































Alteration of PON1 Activity in Adult and Childhood Obesity
2002) and that hypoadiponectinemia was associated with endothelial dysfunction
(Shimabukuro et al. 2003), cardiovascular disease (Kumada et al. 2003) and dia-
betes mellitus (Hotta et al. 2000), we hypothesized that there might be correlations
between antioxidant PON1 activities and adiponectin levels. We analyzed the rela-
tionship of adiponectin concentration to PON1 activity (Bajnok et al. 2008a). To
the best of our knowledge this was the first study to investigate the relationship
between PON1 activity and adiponectin levels. We found a strong positive corre-
lation between these two anti-atherogenic factors (r = 0.41; p < 0.001) (Fig. 2c).
There was a stronger correlation between adiponectin and PON1 among males
(r = 0.49, p < 0.01) than among females (r = 0.37, p < 0.05).
To test if the association between adiponectin and PON1 was independent of
anthropometric and other laboratory parameters, we carried out a multiple regres-
sion analysis. During this test only adiponectin turned out to be an independent
predictor of serum PON1, but none of the other variables that were included in
the model (Table 1). The association between adiponectin and PON1 was indepen-
dent of anthropometric and other parameters, i.e. age, gender, BMI, systolic blood
pressure, insulin resistance index by homeostasis model assessment (HOMA-IR),
LDL-C, HDL-C and lipid peroxidation (measured by thiobarbituric acid-reactive
substances [TBARS]).
Table 1 Multiple regression analysis for PON1 activity as a dependent variable
Variable β P










BMI: Body mass index; BP: blood pressure; HDL-C: high-density
lipoprotein-cholesterol; HOMA-IR: insulin resistance index by home-
ostasis model assessment; LDL-C: low-density lipoprotein-cholesterol;
TBARS: thiobarbituric acid-reactive substances
2.2 Relationship of Resistin to PON1
Resistin levels were higher in the controls than among the obese subjects, with no
differences between the obese subgroups (Fig. 3a). The concentrations of resistin
were similar in the three groups of PON1 phenotypes, and there were no significant







































































































r = 0.28; p<0.05
*p<0.05
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Fig. 3 Resistin levels in the different BMI categories (a), and correlations between resistin level
and BMI (b) and between resistin level and PON1 activity (c) in adult obesity
subjects. Impact of BMI categories on the resistin level remained significant even
after adjustments for age and gender (Bajnok et al. 2008b).
Univariate correlation analysis showed that in the whole population, serum lev-
els of resistin were correlated negatively with BMI and correlated positively with
PON1 activity (Fig. 3b,c).To test if the association of resistin with PON1 existing
in the univariate analysis was independent of anthropometric and other laboratory
parameters, we carried out multiple regression analyses with PON1 as the dependent
variable.
At first, two less well adjusted models (Model A and B) were constructed in
which, beside resistin, the impact of age, sex and BMI were tested (Table 2). In
Model B HDL-C was also included, since PON1 is associated with a subfraction of
HDL. In these models only BMI turned out to be an independent predictor of PON1,
explaining the 12.6% of the variance of PON1. We also constructed a more fully
adjusted model (Model C), applying parameters that are related either to metabolic
syndrome (systolic blood pressure, HDL-C, HOMA-IR) and/or lipid peroxidation
(LDL-C and TBARS). The reason for including these latter two parameters was that
higher levels of cholesterol concentration and lipid peroxidation are associated with
enhanced inactivation of PON1 in an interaction between lipid peroxides and the
sulfhydryl groups of the enzyme.
In the extended model (Model C), BMI ceased to be a significant independent
























































Alteration of PON1 Activity in Adult and Childhood Obesity
Table 2 Multiple regression analysis for PON1 paraoxonase activity as a dependent variable
Model A (R2 = 0.20) Model B (R2 = 0.21) Model C (R2 = 0.22)
Variable B t P β t P β t P
Age 0.08 0.67 0.50 0.04 0.34 0.73 0.05 0.37 .071
Gender −0.09 −0.79 0.44 −0.14 −1.22 0.23 −0.04 −0.27 0.79
BMI −0.42 −3.87 < 0.001 −0.42 −3.87 < 0.001 0.11 0.39 0.70
Resistin 0.14 1.22 0.23 0.14 1.22 0.23 0.11 0.78 0.44
HDL-C − − 0.11 0.82 0.42 0.06 0.34 0.74
LDL-C − − − − − −0.06 −0.42 0.68
TBARs − − − − − −0.41 −3.2 0.002
Systolic BP − − − − − −0.07 −0.35 0.73
HOMA-IR − − − − − −0.23 −1.54 0.13
BMI: Body mass index; BP: blood pressure; HDL-C: high-density lipoprotein-cholesterol;
HOMA-IR: insulin resistance index by homeostasis model assessment; LDL-C: low-density
lipoprotein-cholesterol; TBARS: thiobarbituric acid-reactive substances
predictor of PON1, showing that of the partially related variables, TBARS and BMI,
the variance of PON1 was explained better by TBARS than by BMI (Table 2).
To the best of our knowledge, this is the first report of the relationship between
resistin and PON1. However, when we tested if the association between resistin and
PON1 was independent of anthropometric and other parameters in multiple regres-
sion analysis, resistin was not an independent predictor of PON1. In fact, during this
multivariate analysis only the negative correlation between PON1 and lipid perox-
idation (measured by TBARS) remained significant, and neither the BMI, nor the
age, gender, systolic BP, HOMA-IR, LDL-C or HDL-C were significant predictors
of PON1 activity.
3 Relationship of Adipokines to PON1 in Childhood Obesity
3.1 Association of Adipokines and PON1 Activity in Childhood
Obesity
Genetic polymorphisms in the promoter and coding regions of the PON1 gene
are the main determinants of the enzyme activity, but serum PON1 activity can
be modulated by several other factors. Aging and pathologic states such as renal
disease, diabetes mellitus, cardiovascular disease, and liver cirrhosis are associated
with decreased PON1 activity, and various dietary and lifestyle factors have been
reported to influence serum PON1 activity (Seres et al. 2004; Paragh et al. 1998,
1999; Mackness and Durrington, 1995; Ferré et al. 2006). Smoking has been associ-
ated with reduced PON1 activity and concentrations in patients with coronary artery
























































I. Seres et al.
Paragh et al. 2004), and hormone replacement therapy (Sutherland et al. 2001), have
been demonstrated to increase serum PON1 activity.
Since other factors influencing PON1 activity (smoking, concomitant diseases
like DM2, CRF, CVD) can be present in obese adults, we decided to investi-AQ3
gate PON1 activity in obese children, where the incidence of these factors are
markedly lower. Similar to the results in adult patients, obese children (age: 11.95 ±
1.61 years, BMI: 28.23 ± 4.33 kg/m2) had significantly higher serum leptin levels
(43.61 ± 26.64 vs. 11.69 ± 14.63 ng/ml; p < 0.001) that correlated positively with
their body fat percentage (r = 0.52; p < 0.001). (Body fat percentage (BFP) is a
better characterizing parameter for obesity in childhood than BMI.) We found gen-
der differences in leptin levels both in the obese and the age- and gender-matched
normal-weight groups, and similarly to other studies girls had significantly higher
leptin levels than boys (p < 0.05). Adiponectin levels were significantly lower in
the obese children group compared to the control group (8.59 ± 4.39 vs.12.24 ±
4.86 μg/ml, p <0.001), as was expected. Obese children had significantly lower
PON1 activity (97.31 ± 21.24 vs. 111.44 ± 23.52 U/L; p < 0.01). Similar to adult
obese individuals, we demonstrated an inverse relation between PON1 activity and
leptin levels (r = –0.29, p < 0.05) and a positive relation between PON1 activ-
ity and adiponectin concentrations (r = 0.39; p < 0.01). In order to test whether
the associations of PON1 with leptin and adiponectin existing in the univariate
analysis were independent of other parameters, we carried out a multiple regres-
sion analysis. Adiponectin level also proved to be an independent predictor of
PON1 activity after adjusting for age, sex, BFP, leptin and HDL-C in the model
(Table 3).
Table 3 Multiple regression analysis for PON1 arylesterase as a dependent variable (model R2 =










Age 1.039 2.513 0.068 0.413 0.68
Sex 13.356 7.168 0.326 1.863 0.08
Leptin −0.312 0.180 −0.349 −1.734 0.10
Adiponectin 2.151 0.841 0.453 2.557 0.02
HDL-cholesterol −20.480 15.920 −0.236 −1.286 0.21
Body fat percentage −0.192 0.526 −0.073 −0.365 0.72
3.2 Correlations Between Adipokine Levels and PON1
Phenotypes
Investigating the phenotypic distribution of PON1 in the obese group, we found
differences in the correlations of PON1 activity in the subgroups (Figs. 4 and 5).
We could divide the obese children into two groups: 40 children belonging to the
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r = –0.49 p< 0.05 r = 0.51  p< 0.05
r = –0.51 p< 0.05
Fig. 4 Correlations between PON1 activity and serum leptin levels (a), serum adiponectin levels
(b) and body fat percentage (BFP) (c) in obese children with AB phenotype


















r = 0.41 p<0.05
Fig. 5 Correlation between
PON1 activity and serum
adiponectin level in obese
























































I. Seres et al.
of the obese children had BB phenotype. We did not find any significant differences
in anthropometric and clinical data between the two groups. Obese children with
AB phenotype had a significant correlation between PON1 activity (Fig. 4a,b,c) and
serum leptin (r = –0.49, p < 0.05), adiponectin levels (r = 0.51, p < 0.05) and
BFP (r = –0.51, p < 0.05) whereas children with AA phenotype had a significant
correlation between PON1 arylesterase activity and adiponectin levels (r = 0.41,
p < 0.05; Fig. 5) but with no significant correlation observed between PON1 activity
and the other investigated parameters.
4 Conclusions
Taken together, in a population with a broad range of BMI that could be divided
into three equal groups, we found a significant negative correlation between PON1
activity and BMI (r = –0.503 p < 0.001) that was independent of age, sex and HDL-
C; BMI explained 12.6% of the variance of PON1. Compared to lean subjects,
obese patients had significantly higher leptin and lower adiponectin and resistin
levels and PON1 activity. Serum PON1 activity showed a negative correlation
with leptin (r = –0.38, p < 0.001), while a positive correlation was shown with
adiponectin (r = 0.41; p < 0.001) and resistin. However, only adiponectin turned
out to be an independent predictor of PON1 activity in a multiple regression model
in which other factors, such age, gender, BMI, systolic blood pressure, HOMA-IR,
LDL-C, HDL-C and a marker of lipid peroxidation were also included, beside the
adipokines.
These results were confirmed among children, except resistin that was not
investigated.
The low PON1 activity in obese children is a novel and alarming result.
Previously we had found that serum PON1 activity significantly decreased with age
(Seres et al. 2004). It may mean that the initially higher cardiovascular risk of obese
children caused by lower PON1 activity will be even higher with aging. Therefore,
screening and treatment of these children is especially important to prevent early
manifestations of atherosclerosis.
Our studies suggest that obesity predisposes to accelerated progression of
atherosclerosis throughout our whole lifetime. Childhood obesity also demonstrates
the importance of this pathologic metabolic state, the consequences of which can be
detected only in later adulthood, and that is why the investigation of this population
has become so important. Changed levels of leptin, adiponectin, resistin and PON1
activity, just like 192 Q/R polymorphism determined by phenotypic distribution,
may be useful markers beside the general risk factors in both adult and childhood
obesity.
Acknowledgments This work was supported by a grant from the Hungarian Scientific Research
Fund (OTKA K63025), ETT (Medical Research Council) (243/2006) and Hungarian National
























































Alteration of PON1 Activity in Adult and Childhood Obesity
References
Bajnok L, Seres I, Varga Z et al. (2007) Relationship of endogenous hyperleptinemia to serum
paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in
obese individuals. Metabolism 56:1542–1549
Bajnok L, Csongradi E, Seres I et al. (2008a) Relationship of adiponectin to serum paraoxonase-1.
Atherosclerosis. 197:363–367
Bajnok L, Seres I, Varga Z et al. (2008b) Relationship of serum resistin level to traits of metabolic
syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass
index. Exp Clin Endocrinol Diabetes 116:592–599
Beltowski J, Wójcicka G, Jamroz A (2003) Leptin decreases plasma paraoxonase 1 (PON1) activity
and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic
hyperleptinemia. Atherosclerosis 170:21–29
Beltowski J (2005) Protein homocysteinylation: a new mechanism of atherogenesis? Postepy Hig
Med Dosw 59:392–404
Beltowski J. (2006) Leptin and atherosclerosis. Atherosclerosis 189:47–60
Beltowski J, Jamroz-Wis´niewska A and Widomska S (2008) Adiponectin and its role in cardiovas-
cular diseases. Cardiovasc Hematol Disord Drug Targets 8:7–46
Bouloumie A, Marumo T, Lafontan M et al. (1999) Leptin induces oxidative stress in human
endothelial cells. FASEB J 13:1231–1238
Curat CA, Miranville A, Sengenès C et al. (2004) From blood monocytes to adipose tissue-resident
macrophages: induction of diapedesis by human mature adipocytes. Diabetes 53:1285–1292
Díez JJ and Iglesias P (2003) The role of the novel adipocyte-derived hormone adiponectin in
human disease. Eur J Endocrinol 148:293–300
Dubey L and Hersong Z (2006) Role of leptin in atherogenesis. Exp Clin Cardiol 11:269–275
Ferré N, Marsillach J, Camps J et al. (2006) Paraoxonase-1 is associated with oxidative stress,
fibrosis and FAS expression in chronic liver diseases. J Hepatol 45:51–59
Ferretti G, Bacchetti T, Moroni C et al. (2005) Paraoxonase activity in high-density lipoproteins: a
comparison between healthy and obese females. J Clin Endocrinol Metab 90:1728–1733
Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with
the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778
Ho RC, Davy K, Davy B et al. (2002) Whole-body insulin sensitivity, low-density lipopro-
tein (LDL) particle size, and oxidized LDL in overweight, nondiabetic men. Metabolism 51:
1478–1483
Holvoet P, Mertens A, Verhamme P et al. (2001) Circulating oxidized LDL is a useful marker for
identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:844–848
Holvoet P (2006) Obesity, the metabolic syndrome, and oxidized LDL. Am J Clin Nutr 83:1438
Hotta K, Funahashi T, Arita Y et al. (2000) Plasma concentrations of a novel, adipose-specific
protein, adiponectin, in type 2 diabetic patients, Arterioscler Thromb Vasc Biol 20:1595–1599
Katagiri H, Yamada T and Oka Y (2007) Adiposity and cardiovascular disorders. Disturbance of
the regulatory system consisting of humoral and neuronal signals. Circ Res 101:27–39
Kumada M, Kihara S, Sumitsuji S et al. (2003) Association of hypoadiponectinemia with coronary
artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89
Mackness MI, Durrington PN (1995) Paraoxonase: another factor in NIDDM cardiovascular
disease. Lancet 346:856
Mackness MI, Durrington PN, Mackness B (2004) The role of paraoxonase 1 activity in
cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 4:
211–217
Matsuda M, Shimomura I, Sata M et al. (2002) Role of adiponectin in preventing vascular stenosis:
the missing link of adipo-vascular axis. J Biol Chem 277:37487–37491
Meier U and Gressner AM (2004) Endocrine regulation of energy metabolism: review of pathobio-

























































I. Seres et al.
Mutlu-Turkoglu U, Oztezcan S, Telci A et al. (2003) An increase in lipoprotein oxidation and
endogenous lipid peroxides in serum of obese women. Clin Exp Med 2:171–174
Paragh Gy, Seres I, Balogh Z et al. (1998) The serum paraoxonase activity in patients with chronic
renal failure and hyperlipidemia. Nephron 80:166–170
Paragh Gy, Asztalos L, Seres I et al. (1999) Serum paraoxonase activity changes in uremic and
kidney transplanted patients. Nephron 83:126–131
Paragh G, Töröcsik D, Seres I et al. (2004) Effect of short term treatment with simvastatin and
atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr
Med Res Opin 20:1321–1327
Patel SB, Reams GP, Spear RM et al. (2008) Leptin: linking obesity, the metabolic syndrome, and
cardiovascular disease. Curr Hypertens Rep 10:131–137
Rabe K, Lehrke M, Parhofer KG et al. (2008) Adipokines and insulin resistance. Mol Med 14:
741–751
Rosenson RS (2006) Low high-density lipoprotein cholesterol and cardiovascular disease: risk
reduction with statin therapy. Am Heart J 151:556–563
Seres I, Paragh Gy, Deschene E et al. (2004) Study of factors influencing the decreased HDL
associated PON1 activity with aging. Exp Gerontol 39:56–66
Shimabukuro M, Higa N, Asahi T et al. (2003) Hypoadiponectinemia is closely linked to
endothelial dysfunction in man. J Clin Endocrinol Metab 88:3236–3240
Sjogren P, Basu S, Rosell M et al. (2005) Measures of oxidized low-density lipoprotein and
oxidative stress are not related and not elevated in otherwise healthy men with the metabolic
syndrome. Arterioscler Thromb Vasc Biol 25:2580–2586
Sutherland W, Manning PJ, de Jong SA et al. (2001) Hormone-replacement therapy increases
serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism
50:319–324
Szmitko PE, Teoh H, Stewart DJ et al. (2007) Adiponectin and cardiovascular disease: state of the
art Am J Physiol Heart Circ Physiol 292:1655–1663
Tomás M, Sentí M, García-Faria F et al. (2000) Effect of simvastatin therapy on paraoxonase
activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb
Vasc Biol 20:2113–2119
Uzun H, Zengin K, Taskin M et al. (2004) Changes in leptin, plasminogen activator factor and
oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable
gastric banding. Obes Surg 14:659–665
Varga Z, Paragh G, Seres I et al. (2006) Hyperleptinemia is not responsible for decreased
paraoxonase activity in hemodialysis patients. Nephron Clin Pract 103:114–120
Wannamethee SG, Tchernova J, Whincup P et al. (2007) Plasma leptin: associations
with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease.
Atherosclerosis 191:418–426
Weinbrenner T, Schröder H, Escurriol V et al. (2006) Circulating oxidized LDL is associated with

























































This is an Author Query Page Integra
Chapter
Q. No. Query
AQ1 please check BMI = body mass index
AQ2 please define ‘ox-LDL’
AQ3 please define these abbreviations
